Archive |
Structure-Based Drug Design will crystallisation ‘chaperones’ make all proteins crystallisable?
By Dr Chun-wa Chung
Macromolecular x-ray crystallography is usually an integral part of small molecule drug discovery for soluble targets. Recent advances in the crystallography of membrane proteins have opened up the prospect of extending structure-based methods into these well validated target classes.
more...
A Perspective on Scientific Innovation in the Pharmaceutical Industry
By Dr Joseph B. Bolen
With a tarnished reputation and a lack of sustainable innovation this article argues that, maybe, it is time for the pharmaceutical industry to look more closely at balancing the commercial needs of their organisations with the requirement to create the correct culture and environment for human innovation and creativity.
more...
Predictive Tests and Personalised Medicine
By Dr Eddie Blair
Acceptance of the personalised medicines paradigm is strictly dependent on this approach clearly benefiting patients with minimal effects on the actual delivery of healthcare.
more...
The growth of personalised medicine will drive alliances between diagnostic and pharmaceutical industries
By Loïc Kubitza
With the growing encouragement of global drug approval agencies and pressure from healthcare payers, this article argues that personalised medicine will have a significant theme in the M&A and licensing activities of pharmaceutical and diagnostic companies, accelerating the development of new diagnostics for personalised medicine in the future.
more...
Multiplexing for Biological Relevance in High Throughput Screening
By William P. Downey, Dr Jennifer Hartigan and Cindy Liu
The multiplexed assay is a technique used increasingly in high throughput screening (HTS) labs to study the complex environment of a target, according to HighTech Business Decisions’ (HTBD) industry report High Throughput Screening: New Strategies, Success Rates, and Use of Enabling Technologies.
more...
Molecular Imaging Approaches
By Dr Susanta K. Sarkar
The current challenges facing drug discovery and development in terms of attrition are well documented. This article discusses how molecular imaging approaches from bench to bedside can not only streamline drug development, but also open up new opportunities in the treatment management of targeted therapies.
more...
Harnessing Fragment-based Drug Discovery at CRT
By Dr Andrew P Turnbull and Dr Martin E Swarbrick
In the past decade, fragment-based drug discovery (FBDD) has gained increasing popularity in the pharmaceutical industry as a powerful alternative and complement to traditional high-throughput screening (HTS) as a source of preliminary hits for drug discovery.
more...
1536 Progress - Done Deal but Difficult Transition?
By Dr John Comley
After nearly 15 years of challenging maturity 1536 adoption, particularly in primary screening, finally appears to have taken hold.
more...